Table 2.

Adverse events of the overall study population with moderate-to-severe plaque psoriasis, n (%).

Adverse events	Analysis set (n = 106)	Secukinumab 150 mg (n = 47)	Secukinumab 300 mg (n = 59)
Any AE	50 (47.2)	23 (48.9)	27 (45.8)
Discontinued treatment due to an AE (n)	1	0	1
Reported AE
Nasopharyngitis	10 (9.4)	4 (8.5)	6 (10.2)
Superficial skin bacterial infection	6 (5.7)	4 (8.5)	2 (3.4)
Upper respiratory infection	4 (3.8)	1 (2.1)	3 (5.1)
Urticaria	6 (5.7)	2 (4.3)	4 (6.8)
Eczema	5 (4.7)	2 (4.3)	3 (5.1)
Mucocutaneous fungal infection	2 (1.9)	1 (2.1)	1 (1.7)
Pruritus	5 (4.7)	2 (4.3)	3 (5.1)
Fatigue	2 (1.9)	0	2 (3.4)
Diarrhea	1 (0.9)	1 (2.1)	0
Pain	4 (3.8)	1 (2.1)	3 (5.1)
Facial dermatitis	2 (1.9)	0	2 (3.4)
Somnolence	4 (3.8)	2 (4.3)	2 (3.4)
Insomnia	1 (0.9)	0	1 (1.7)
Lentigines	2 (1.9)	0	2 (3.4)
Prolonged menstrual cycle	1 (0.9)	0	1 (1.7)
Herpes simplex	1 (0.9)	1 (2.1)	0
Increased liver enzymes	1 (0.9)	0	1 (1.7)
Hypertension	1 (0.9)	0	1 (1.7)
Increased temperature	1 (0.9)	0	1 (1.7)

AE: Adverse event.